New Report on Insurance Barriers for PCSK9 Inhibitors Featured at National Cardiovascular Health Policy Summit
WASHINGTON -- New data show that health plans reject prescriptions for cholesterol-lowering medication for women, southerners, and Black and Hispanic patients more often than for white patients. The findings appear in "Rejected: How Life-Saving Heart Medication Eludes Women, Southerners, and People of Color," a new policy brief from the Partnership to Advance Cardiovascular Health.
Key Findings
The report details 2019-2021 commercial insurance claims data for cholesterol-lowering PCSK9 inhibitors, which show that:
Some plans rejected three-fourths or more of claims:
"This information is concerning," says cardiologist Dharmesh Patel, MD. "We see higher denial rates in communities that are already high risk for deadly cardiovascular events. Heart disease is the leading cause of death in the United States, and yet patients who most need FDA-approved medications to prevent adverse events are being denied."
Patel is president of the Partnership to Advance Cardiovascular Health.
About PSCK9 Inhibitors
PCSK9 inhibitors, which first came to clinic in 2015, are:
The findings were announced during the fifth annual Cardiovascular Health Policy Summit hosted by the Partnership to Advance Cardiovascular Health. Patient advocates, clinicians, and policymakers gathered to discuss the barriers patients face in accessing these cholesterol-lowering drugs.
Original source can be found here.